Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 785934, 7 pages
http://dx.doi.org/10.1155/2010/785934
Clinical Study

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

1Service d'Oncologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
2Groupe Hospitalier Pitié Salpétrière, Service d'Hépato-Gastroentérologie, Paris, France
3Centre Paul Papin, Angers, France
4Hôpital Claude-Huriez, Lille, France
5Hôpital Foch, Suresnes, France
6Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France
7Eli Lilly, France

Received 29 July 2009; Accepted 8 February 2010

Academic Editor: Stefano Cascinu

Copyright © 2010 C. Louvet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. L. B. Saltz, J. V. Cox, C. Blanke et al., “Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group,” The New England Journal of Medicine, vol. 343, no. 13, pp. 905–914, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Y. Douillard, D. Cunningham, A. D. Roth et al., “Irinotecan combined with fluorouracil compared with fluorouracil alone. As first-line treatment for metastatic colorectal cancer: a multicentre randomised trial,” Lancet, vol. 355, no. 9209, pp. 1041–1047, 2000. View at Google Scholar · View at Scopus
  4. C. H. Köhne, E. Van Cutsem, J. Wils et al., “Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4856–4865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. de Gramont, A. Figer, M. Seymour et al., “Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 2938–2947, 2000. View at Google Scholar · View at Scopus
  6. R. M. Goldberg, D. J. Sargent, R. F. Morton et al., “A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 23–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. P. F. Engstrom, A. B. Benson III, Y. J. Chen et al., “Colon cancer clinical practice guidelines in oncology,” Journal of the National Comprehensive Cancer Network, vol. 3, no. 4, pp. 468–491, 2005. View at Google Scholar · View at Scopus
  8. T. André, C. Louvet, F. Maindrault-Goebel et al., “CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer,” European Journal of Cancer, vol. 35, no. 9, pp. 1343–1347, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Tournigand, T. André, E. Achille et al., “FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study,” Journal of Clinical Oncology, vol. 22, no. 2, pp. 229–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Shih, V. J. Chen, L. S. Gossett et al., “LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes,” Cancer Research, vol. 57, no. 6, pp. 1116–1123, 1997. View at Google Scholar · View at Scopus
  11. A. A. Adjei, “Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent,” Clinical Cancer Research, vol. 10, no. 12, pp. 4276s–4280s, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Hazarika, R. M. White, J. R. Johnson, and R. Pazdur, “FDA drug approval summaries: pemetrexed (Alimta®),” Oncologist, vol. 9, no. 5, pp. 482–488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Cripps, M. Burnell, J. Jolivet et al., “Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study,” Annals of Oncology, vol. 10, no. 10, pp. 1175–1179, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. W. John, J. Picus, C. D. Blanke et al., “Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study,” Cancer, vol. 88, no. 8, pp. 1807–1813, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Louvet, “Pemetrexed in advanced colorectal cancer,” Oncology, vol. 18, no. 13, pp. 56–62, 2004. View at Google Scholar · View at Scopus
  16. C. Niyikiza, S. D. Baker, D. E. Seitz et al., “Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy,” Molecular Cancer Therapeutics, vol. 1, no. 7, pp. 545–552, 2002. View at Google Scholar
  17. H. Hochster, E. Kettner, H. Kroning et al., “Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer,” Clinical Colorectal Cancer, vol. 5, no. 4, pp. 257–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. E. K. Rowinsky, M. Beeram, L. A. Hammond et al., “A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies,” Clinical Cancer Research, vol. 13, no. 2, pp. 532–539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar · View at Scopus
  20. S. J. Green and S. Dahlberg, “Planned versus attained design in phase II clinical trials,” Statistics in Medicine, vol. 11, no. 7, pp. 853–862, 1992. View at Google Scholar · View at Scopus
  21. M. Mabro, C. Louvet, T. André et al., “Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer,” American Journal of Clinical Oncology, vol. 26, no. 3, pp. 254–258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Mabro, P. Artru, T. André et al., “A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients,” British Journal of Cancer, vol. 94, no. 9, pp. 1287–1292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. A. F. Sobrero, J. Maurel, L. Fehrenbacher et al., “EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2311–2319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. B. J. Giantonio, P. J. Catalano, N. J. Meropol et al., “Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1539–1544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. F. Smit, S. A. Burgers, B. Biesma et al., “Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2038–2045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Underhill, D. Goldstein, V. A. Gorbounova et al., “A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer,” Oncology, vol. 73, no. 1-2, pp. 9–20, 2007. View at Publisher · View at Google Scholar · View at Scopus